Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Mar 20, 2021 12:32pm
203 Views
Post# 32845068

RE:RE:New poster on liver inflammation at Endo

RE:RE:New poster on liver inflammation at EndoProbably right. Those endocrine types just can't keep a secret....  Maybe get it to PR outlets Monday. 

Dr. Stanley and Fourman at it again with genetic analysis. This time for immune system effects as measured in the blood plasma from the Phase 2 participants. I think they've learned as much, if not more, about the MOA of their drug on the liver via the 90 person NAFLD Phase 2 trial than others at this stage. They are real assets to Grinspoons lab and this project. Looks like it extends their previous genetic work that hinted at impacting genes involved in liver cancer. Adds another way the drug interacts with the liver and, this time, the immune system for the liver, to bring it back to health like they saw in the trial.  Solid!


jfm1330 wrote: Maybe it's the reason for the little rise of the last few days. 

jfm1330 wrote: Strange to publish that on a friday night.


https://www.abstractsonline.com/pp8/#!/9188/presentation/2240



https://www.theratech.com/theratechnologies-announces-new-data-demonstrating-tesamorelins-positive-effect-on-immune-response-linked-to-liver-inflammation/




<< Previous
Bullboard Posts
Next >>